AEMS Corp Raises $95K Seed for Automated Formulation Screening Platform

AEMS Corp Closes $95K Seed Round

AEMS Corp, a Denver, Colorado-based formulation engineering company, has raised $95,000 in seed funding. The round was recorded on September 18, 2026. No lead investor was named, and no additional investors were listed.

What AEMS Corp Does

AEMS Corp addresses viscosity problems in high-concentration biologic drugs, including siRNA and subcutaneous injectables. The company's approach centers on an automated microscale screening platform that runs more than 600 experiments per week using as little as 20 microliters of formulation.

That throughput-to-volume ratio is the technical core of the business: it allows formulation screening at a scale and sample size that would be difficult to match with conventional methods.

Company Background

AEMS Corp was founded in 2019 by Scott Compel and Alexander Hendricks. The company emerged out of a materials-science discovery at Colorado State University.

Its path to the pharmaceutical formulation market was not direct. AEMS Corp began as an agricultural technology startup selling an organic seed sanitizer. It later pivoted into pharmaceutical formulation services.

The company became the first startup based at the CSU Spur campus before moving to larger labs in Fort Collins.

Round Details

• Round type: Seed
• Amount: $95,000
• Currency: USD
• Date: September 18, 2026
• Lead investor: Not disclosed
• Additional investors: None listed

Why This Matters

High-concentration biologic drugs — including siRNA therapeutics and subcutaneous injectables — present formulation challenges, with viscosity among the most significant. Solving those challenges is a prerequisite for delivering many of these therapies in practical, patient-friendly formats such as subcutaneous injection.

AEMS Corp's platform is designed to screen formulations at microscale, running hundreds of experiments weekly on minimal sample volumes. For drug developers working with scarce or expensive biologic materials, that efficiency can matter.

The company's pivot from agricultural technology to pharmaceutical formulation services reflects a repositioning of its underlying materials-science capabilities toward a higher-value market.

Acquisition Angle

AEMS Corp offers a formulation engineering capability paired with an automated screening platform. For acquirers in drug development services, contract research, or formulation technology, the company represents an early-stage asset with a differentiated screening approach and an established lab footprint in Fort Collins.

Its origin as a CSU Spur campus startup and its Colorado State University research roots provide a regional academic pipeline context.

Summary

AEMS Corp, founded in 2019 by Scott Compel and Alexander Hendricks, raised $95,000 in seed funding on September 18, 2026. The Denver-based company uses an automated microscale screening platform to solve viscosity problems in high-concentration biologic drugs, including siRNA and subcutaneous injectables. It pivoted from an agricultural technology origin into pharmaceutical formulation services and was the first startup based at the CSU Spur campus before relocating to larger labs in Fort Collins.